Research programme: infectious disease diagnostics - Molecular Insight Pharmaceuticals/Syracuse University
Alternative Names: MIP 160; Tc 99m-labeled chemotactic peptideLatest Information Update: 25 Mar 2008
At a glance
- Originator Molecular Insight Pharmaceuticals; Syracuse University
- Class Imaging agents; Radiopharmaceuticals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Infections
Most Recent Events
- 21 Oct 2003 Preclinical trials in Diagnostic imaging of Infections in USA (unspecified route)